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1. Introduction 
By definition, pharmacoepidemiology is the study of the use and the effects of drugs, 
medical devices or vaccines in large numbers of people (Strom, 1994). Epidemiologists 
working in the pharmaceutical and biotechnology industry use the principles of descriptive 
epidemiology in addition to analytical and clinical epidemiological applied concepts and 
methods to assess the impact, use and effects of these products in the population and in 
clinical trial settings. As an evolving field, the influence of pharmacoepidemiology 
continues to be broadened with increasing demands for a comprehensive understanding of 
the patient population within the development and post-authorization phases of a product’s 
lifecycle.  
Before exploring the role of epidemiology within the drug lifecycle, some familiarity with 
the phases of drug development is necessary. Herein, a brief overview of the drug 
development lifecycle is provided. The intent is not to present a detailed outline of the 
regulatory process by which a new drug is brought to market, but rather a selective review 
to offer context for the potential clinical and scientific contributions of the field of 
epidemiology. The established framework of a drug’s lifecycle includes four phases: 
discovery and research (pre-clinical phase), clinical development, regulatory review and 
approval, and post-authorization (Table 1). Typically, discovery begins with industry or 
academic researchers testing tens of thousands of compounds to determine potential 
therapeutic benefit. Few compounds proceed to the next stage, which involves testing 
candidate drugs in animals to ensure there is no development of limiting toxic effects. It is 
estimated that only 1 out of 50 candidate drugs will move past the discovery phase and into 
clinical development trials in humans (phases I, II and III). Clinical trials in humans 
represent the most expensive phase of development. Cost estimates range in the hundreds 
of millions, and for every five drugs entering late-phase clinical trials, only one will 
eventually make it to market and generate revenue for the manufacturer (Tufts, 2001). 
Additionally, during this time, there is ongoing parallel work related to drug substance 
manufacturing (e.g., formulation activities, analytical and microbiological methods 
development and validation) to support development activities. 
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Phase Title Timing Brief Description
Preclinical Discovery and 
research 
1 to 6 
years 
Preclinical testing - initiation for synthesis, 
purification and formulation of the drug; for 
conducting biology/pharmacology, 
pharmacokinetics and metabolism evaluations; 
for conducting GLP toxicity/safety evaluations 
including toxicology, pathology, mechanistic 
toxicology and bioanalytical support; for 
identification of potential drug-drug interactions. 
Phases I-III Clinical 
development 
6 to 11 
years 
 
Phase I – The “safety” phase. Smaller clinical 
trials using healthy volunteers to determine the 
drug’s basic pharmacokinetic and 
pharmacologic properties and safety profile in 
humans. 
Phase II - The “learn” phase. These trials are 
focused on evaluating effective and safe doses 
in persons with the target disease/disorder 
under consideration.  
Phase III - The “confirm” phase. These trials are 
usually the most extensive and most expensive 
part of drug development. These trials often are 
controlled (usually with placebo) and are 
designed to verify the safety and efficacy of a 
drug in large numbers, typically several 
hundred to several thousand persons, within 
the target population. 
Peri-
approval 
Regulatory 
review and 
approval 
0.6 to 2 
years 
After completing phases I-III, the manufacturer 
submits a registration dossier containing all non-
clinical (eg, toxicology, pharmacology), efficacy 
and safety data in addition to manufacturing 
quality data for review by regulatory agencies 
(eg, FDA – United States Food and Drug 
Administration, EMA – European Medicines 
Agency). The agency evaluates the drug’s safety, 
efficacy and labeling with specific emphasis on 
public health impact and the benefit-risk profile 
of the drug.  
Phase IV  Post-
authorization/
Post-market 
surveillance 
11 to 14 
years 
Conditioned on the regulatory approval of the 
drug and involves ongoing safety evaluation of 
the drug (through periodic spontaneous 
reports, which may also be supplemented with 
observational studies) once it is used within the 
real-world setting with the emphasis of 
maintaining the benefit-risk profile. 
Adapted from FDA review.org. http://www.fdareview.org/approval_process.shtml and Hartzema et 
al., 1998. 
Table 1. Description of drug development lifecycle. 
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Epidemiological data and methods are utilized during each phase presented above; 
however, the degree of involvement is dependent on the current knowledge base and 
interactions between factors that are specific to the molecule (eg, biologic vs. drug; oral vs. 
injectable), the disease (eg, hypertension vs. cancer), other inventions (eg, competitive 
and/or complimentary products) and the patient (eg, males in their mid-40s vs. adolescent 
females) (Figure 1). Furthermore, underlying these interactions is the impact of patient’s 
knowledge, attitude and behaviors about the study drug or disease as well as interactions 
with the geographical and social environment. 
 
Fig. 1. Conceptual framework for the potential impacts for epidemiological data and 
methods within the clinical development phase 
As there is a wide spectrum of data needs and requirements during any drug’s lifecycle, a 
summary, including a real-world example, of the epidemiological data and methods utilized 
specifically during clinical development phase is helpful. To illustrate how epidemiologists 
can facilitate clinical development, this review provides a practical overview of the type of 
research questions addressed with epidemiological data and methods. In addition, a case 
study describing how epidemiological data was used to support the registration of 
onabotulinumtoxinA (BOTOX®, Allergan, Inc., Irvine, CA, USA) for treatment of headaches 
in adults with chronic migraine is presented. Using this framework, data generation is 
focused on the population epidemiology, treated natural history and burden of chronic 
migraine. The review is not meant to be a guidance document, but rather an illustration 
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highlighting the importance of an evidence-based understanding of the patient population in 
order to adequately measure efficacy, to evaluate and maintain the safety of a drug during 
development and to prepare for post-registration activities once the product is available in the 
market. Although not the focus of this chapter, the role of pharmacoepidemiologists does not 
end at approval. In the post-authorization environment, the need shifts more toward 
understanding the patient population actually exposed to the drug, under what conditions, 
and with what outcomes, in the “real world” setting. For example, is the drug being used in 
patients not included in clinical trials? Is there compliance with the labeling? Is the safety and 
effectiveness similar to what was observed in clinical trials? If not, why not? To respond to 
these types of research questions, designs such as drug utilization studies, post-authorization 
safety and effectiveness studies should be explored. 
2. Defining the target patient population 
Epidemiology data can be used to estimate the size of the target population and its 
geographic distribution, quantify and describe demographic and clinical characteristics, and 
help determine the potential public health impact of a target treatment once the drug is 
marketed and prescribed within the general population. These data are critically important 
to help guide commercial and clinical development strategies; therefore, it is most useful to 
obtain this information starting early in phase II and continuing, as needed, through phase III.  
By the time a drug enters clinical development, a sponsor (e.g. pharmaceutical or 
biotechnology company) has typically already assessed, at least at a high level, the incidence 
and prevalence of disease, the unmet needs for treatment, and the burden of disease, in order 
to have some understanding of where the drug might fit in the treatment armamentarium.  
During the phase II and phase III clinical trials, a more robust understanding of the target 
patient population becomes necessary in order to evaluate efficacy and safety and to 
consider the optimal position within the current treatment paradigm. Therefore, 
epidemiologists rely on observational study design (eg, disease registries, cohort studies, 
cross-sectional studies, case-control studies) to generate data to answer more specific 
questions about the population epidemiology and disease natural history. (Strom, 1994; 
Hartzema et al., 1998) The population epidemiology of a disease provides estimates of the total 
number of people currently impacted as well as future estimates by utilizing current and 
projected prevalence and incidence rates. Aiming to stratify prevalence and incidence rates by 
country or geographic region, age, gender and, when appropriate, factors such as race or 
seasonal variation can provide a more complete picture of the demographic profile of the 
target population. Additionally, the symptom profile, disease-related morbidity and mortality, 
should be detailed in this context. The disease natural history refers to the progression of a 
disease from onset until either recovery or death. It encompasses factors related to the 
behavior of a disease so that the clinical course including the disease onset, disease duration, 
progression, and disease outcomes are well documented. Available treatment practices should 
be evaluated, as this often alters disease progression. Risk factors, including biological, genetic 
or environmental, should be discussed in terms of disease outcomes or progression rather than 
onset. It is worth noting that because typical drug development, with the exception of vaccine 
development, is not focused on disease prevention, but rather remission or recovery, then the 
focus is on understanding factors that alter disease duration and endpoints rather than disease 
onset and is referred to as the treated natural history. 
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Observational studies are used to generate data describing the target patient population in 
the “real world” rather than in the controlled “clinical trials” environment. Multiple 
observational approaches can be utilized, depending on research objectives. Cross-sectional 
studies collect data on various characteristics, experiences and behaviors in relation to 
exposure, outcomes and/or other variables of interest at the same time point. These studies 
can be either population-based or represent a select population, such as those in a clinic or 
those who have access to the internet. Cohort studies can be conducted prospectively or 
retrospectively, and identify and follow subjects according to either exposure or disease 
occurrence to assess multiple outcomes. Commonly utilized examples cohort studies 
include retrospective electronic health care database analyses and disease registries. Case-
control studies are typically hypothesis testing, in that the design aims to quantify the odds 
of having an exposure given an outcome or the reverse depending on what is known. 
Subjects are predefined as either case or controls based on whether the patient has the 
disease or outcome of interest, and then patients’ histories are compared for differences in 
exposure or other potential risk factors. When evaluating which study design is most 
appropriate, pharmacoepidemiologists assess and select study designs based on the 
particular research question, urgency of the data request, availability of data sources, 
concerns of internal and external validity, and feasibility and practicality, and cost 
(Hartzema et al., 1998). 
It is not feasible to discuss every situation for which epidemiological data can be utilized in 
a single chapter; however, one of the key drivers of research is the need to put into context the 
clinical trial findings, for example, when monitoring safety within double-blind, placebo-
controlled trials. In order for safety physicians to effectively monitor safety without unblinding 
patients in clinical trials, outcomes that are associated with natural disease course should be 
distinguished from adverse outcomes that are potentially drug-related, referred to as adverse 
drug reactions. This situation encompasses the potential for confounding by indication and 
reflects the importance in adequately “teasing apart” adverse events caused by the disease 
itself versus adverse events caused by the drug, or even a potential disease-drug interaction or 
when the adverse event may occur in the disease background but be exacerbated or prolonged 
by the drug. To clarify with examples, confounding is when a variable (e.g., adverse event 
such as weight gain) is a risk factor for a disorder (e.g., CM) among nonexposed persons (e.g., 
those not on study drug) and is associated with the exposure of interest (e.g., study drug) in 
the population from which the cases derive, without being an intermediate step in the causal 
pathway between the exposure and the disorder (Salas M et al., 1999). Given the potential 
complexity of natural clinical course of a disease, it is evident that if background rates within 
the target population unexposed to the drug are adequately quantified, then the determination 
of drug- or disease-related outcomes can be strengthened beyond the clinical assessment of 
treatment causality. 
By answering questions in Table 2, row 1, epidemiologists support clinical development by 
providing strategic insight into defining the appropriate target patient profile and the 
predicted public health benefit. Defining diagnostic criteria and properly characterizing the 
target patient population will help in understanding the disease outside the clinical trial 
environment to ensure that clinical trials are evaluating treatments in the most appropriate 
target patient population. Epidemiological data can also help physicians monitor the safety 
without unblinding patients in clinical trials, and if a potential risk is identified, can help to 
estimate the impact in actual clinical practice.  
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Category Description Key Research Questions 
Population 
Epidemiology 
An overview of the condition 
for which the product is being 
developed, including 
incidence rate (rate of new 
cases in a population within a 
specified time frame), 
prevalence rate (number of 
existing cases) stratified by 
geography, patient 
demographics in a population 
within a specified time frame, 
clinical characteristics, trends 
over time and 
recommendations relating to 
studies needed to address data 
gaps  
• What are the disease rates (eg, age-, 
gender-stratified)? More specifically, 
which populations are most affected 
both currently and prospectively by 
the disease? 
• What is the disease severity in relation 
to morbidity and mortality? 
• What is the disease duration? 
• What is the severity of the disease 
symptoms in relation to disease 
duration? 
• What are the characteristics (eg, age, 
correlated clinical deficiencies) of the 
disease onset? 
• What are the key drivers (eg, comorbidity 
profile, health care access) with regard 
to disease progression? 
Treated 
Natural 
History 
An overview of clinical course 
of the condition for which the 
product is being developed. 
Focused on detailing disease 
progression, defining a patient 
profile, quantifying rates of 
common comorbidities, 
treatments and treatment 
practices, disease outcome 
rates (e.g. morbidity, 
mortality, survival) and rates 
of potential drug-related 
adverse events. This report 
provides information to 
understand the types of 
adverse events that are 
associated with the planned 
indication and with its 
common therapies and to 
quantify the frequency (ie, 
risk) of these adverse events 
within the general population 
and to estimate the potential 
benefit of the product under 
development. 
• What are the characteristics of the 
disease onset? 
• Age 
• Correlated deficiencies 
• Potential covariates (eg, stress, 
environmental triggers) 
• What are the characteristics of the 
disease window? 
• How long does the average person 
have the disease? 
• What occurs in extreme cases? 
• What are the common 
comorbidities? 
• Understand differences with regard 
to factors such as: 
• Nutrition 
• Psychology 
• Health care 
• Socioeconomic status (SES) 
• What are the characteristics of the 
disease endpoint? 
• Does disease endpoint depend on 
disease severity? 
• Outline major and minor effects of 
the disease: 
• Are there any permanent losses 
of ability? 
• Correlate that loss of ability to 
quality of life 
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Category Description Key Research Questions 
• Understand the percentage of 
reoccurrence of disease after 
initial onset 
• What is the disease profile, combining 
genetic, environmental and cultural 
factors that may contribute to disease? 
• Who is most likely to be diagnosed 
with the disease? 
• Who is most likely to have severe 
progression of the disease? 
• Are there cultural biases in relation 
to treatment and/or disease? 
Burden of 
Disease 
An overview focused on the 
negative disease-related 
impact for the individual 
suffering and his or her social 
network, as well as the 
associated direct and indirect 
costs in the real-world setting. 
• What is the humanistic burden 
associated with the disease? 
• Health-related quality of life 
assessments 
• Disability assessments 
• Disease-related impacts (eg, 
depression, anxiety, sleep) 
• What is the societal burden associated 
with the disease? 
• Associated family and social burden  
• Lost employment/education (ie, 
absenteeism) 
• Suboptimal work productivity (ie, 
presenteeism) 
• Caregiver burden 
• What is the economic burden associated 
with the disease? 
• What are the direct costs associated 
with the disease? 
• Healthcare encounters (eg, 
emergency room (ER) visits, 
hospitalizations, office visits) 
• Over-the-counter and 
prescription medications 
• Treatment-related procedures 
• Diagnostic evaluations 
• Patient co-payments  
• What are the indirect costs associated 
with the disease? 
• Monetized assessment of work- or 
school-related impact 
• Absenteeism and presenteeism 
Table 2. Overview of epidemiology support for clinical development.  
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Real-world application can provide significant insights when discussing the role of 
epidemiology within the pharmaceutical or biotechnology development industry. When the 
onabotulinumtoxinA development program for chronic migraine was initiated, the 
International Headache Society had not standardized diagnostic criteria for chronic 
migraine, which had broadly been defined as those with migraine and 15 or more headache 
days per month. In subsequent years, and in parallel to the phase II and phase III trials, 
multiple diagnostic criteria were proposed to the clinical community and it proved difficult 
to create criteria applicable to clinical practice, clinical trials and population-based studies. 
As a consequence, a wide range of terms with a multiplicity of definitions were applied to 
persons with what is now defined as chronic migraine (Manack et al., 2009, 2010; Olesen 
2006; Olesen et al., 2006). Due to the timing of this evolution relative to when the 
onabotulinumtoxinA trials were completed, the chronic migraine diagnostic criteria utilized 
in the phase III studies were in alignment, but were not identical to the most recent criteria 
proposed by the International Headache Classification Committee within the International 
Classification of Headache Disorders (ICHD) guidelines.  
To ensure that the safety and efficacy trial findings were representative of findings for those 
diagnosed under the most recent ICHD criteria (ICHD-2R), profile concordance between 
criteria was evaluated within a large patient population that physicians identified as having 
chronic migraine. Epidemiological assessments of daily diary data were completed to 
compare the demographic and headache symptom profiles for the several of the proposed 
chronic migraine diagnostic criteria (Silberstein et al., 2011; Lipton et al., 2011). Within the 
test database, the ICHD-2R definition was set as the gold standard and sensitivity and 
specificity analyses against the onabotulinumtoxinA phase III diagnostic criteria were 
conducted. Assessments supported that the patient profiles of the chronic migraine 
diagnostic groups were similar across demographic profiles and headache characteristics. 
Results from the epidemiological assessments all supported the initial hypothesis that the 
chronic migraine population evaluated in the phase III clinical studies was not identical to, 
but was clinically representative of, the target population of patients currently defined by 
the ICHD-2R criteria and fully representative of patients who would be receiving 
onabotulinumtoxinA treatment. 
Additionally, due to the chronic migraine classification variability, it was difficult to 
determine the disease prevalence during the time of the development program. To gain a 
better understanding of the actual number of people suffering from chronic migraine, a 
systematic literature search was conducted to summarize population-based studies 
reporting prevalence and incidence of chronic migraine and to explore variation across 
studies. Sixteen publications representing 12 studies were accepted as having a relevant 
study design and population. None presented data on chronic migraine incidence. The 
prevalence of chronic migraine ranged between 0 and 5.1%, with estimates typically in the 
range of 1.4–2.2% (Natoli et al., 2010). Prevalence varied by World Health Organization 
region and gender. Heterogeneity across studies and lack of data from certain regions left an 
incomplete picture; however, the review offered a comprehensive overview of the current 
knowledge base and provided direction for future research (Natoli et al., 2010). 
Expanding beyond the assessments of drug safety and efficacy, the onabotulinumtoxinA 
development program incorporated a significant amount of epidemiological research to 
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generate data that established the clinical course of chronic migraine and distinguished it 
from episodic migraine (migraine with less than 15 days of headache per month). Three 
robust epidemiological studies were utilized as data sources (Table 3). Of note, and 
emphasizing the collaboration between academia and industry, only one of these studies 
was initiated and completely sponsored by the manufacturer.  
Study Design Duration Sponsorship 
American 
Migraine 
Prevalence and 
Prevention 
(AMPP) Study 
(Buse et al., 2010; 
Lipton et al., 
2007) 
Longitudinal, prospective, 
population-based, mailed 
survey identified 
individuals by screening 
120,000 US households 
representative of the US 
population, resulting in a 
pool of 24,000 respondents 
with severe headache who 
have been followed 
annually. 
5 years Study initially funded by 
an unrestricted grant to the 
National Headache 
Foundation by Ortho-
McNeil Neurologics, Inc., 
Titusville, NJ, USA. 
Additional analyses and 
data collection focused on 
chronic migraine 
epidemiology funded by 
Allergan Inc., Irvine, CA. 
German 
Headache 
Consortium 
(GHC) Study 
(Katsarava et al., 
2011) 
Longitudinal, prospective, 
population-based, 
mailed/telephone survey 
used questionnaires sent 
annually to a random 
sample of 18,000 
individuals aged 18-65 
residing in 
demographically diverse 
regions, including a large 
and midsize city and a 
rural area of Germany. 
3 years Study funded by the 
German Research Council 
(DFG), German Ministry of 
Education and Research 
(BMBF), and European 
Union and conducted 
through the Department of 
Neurology in Essen. 
Additional analyses 
focusing on chronic 
migraine epidemiology 
supported by Allergan, 
Inc., Irvine, CA, USA. 
International 
Burden of 
Migraine Study 
(IBMS) 
(Blumenfeld et 
al., 2011; Payne 
et al., 2011) 
Cross-sectional web-based 
survey identified panelists 
through respondents who 
had previously reported 
suffering from headaches 
or migraine. Nine 
countries surveyed: United 
States, Canada, Germany, 
United Kingdom, France, 
Italy, Spain, Australia and 
Taiwan. 
1 year Study funded by Allergan, 
Inc., Irvine, CA, USA. 
Table 3. Summary of chronic migraine epidemiological studies 
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Data from the three independent studies (AMPP study, GHC study, IBMS) concluded that 
the two headache disorders (chronic migraine and episodic migraine) differ with regard to 
clinical definitions, prevalence, symptom profiles, functional consequences and disabilities, 
indirect and direct costs, patterns of consultation and treatment, rates of comorbidities and 
risk factors (Manack et al., 2010, 2011; Bigal et al., 2008, Buse et al., 2010, 2011 in press; 
Blumenfeld et al., 2011; Katsarava et al., 2011; Stewart et al., 2010; Munakata et al., 2009). 
Data confirmed what had been previously hypothesized by the headache community: that 
chronic and episodic forms of migraine exist along a clinical spectrum with remission and 
progression between the two, but the disorders are distinct and differ in degree and kind 
(Lipton, 2009; Lipton and Chu, 2009) (Table 4). 
Variable Chronic Migraine Episodic Migraine 
Clinical description ICHD-2 criteria for migraine 
and average ≥15 headache 
days/month 
ICHD-2 criteria for migraine 
and average <15 headache 
days/month 
Prevalence, %** 1.4-2.2 11 
Age, mean (SD) 47.7 (14.0) 46.0 (13.8) 
Race, % Caucasian 78.6 80.0 
BMI, mean (SD) 29.8 (8.3) 29.2 (7.9) 
Cutaneous allodynia, % 68.2 63.2 
Headache duration 
with medication 
(average in hours) 
 mean SD 
24.1 (46.8) 12.8 (25.0) 
Headache duration 
without medication 
(average in hours) 
 mean SD 
65.1 (62.2) 38.8 (39.9) 
Headache pain 
intensity, % severe 
92.4 78.1 
Comorbid conditions More likely to report or meet 
criteria for psychiatric, pain, 
respiratory and 
cardiovascular comorbid 
conditions 
Less likely to report or meet 
criteria for psychiatric, pain, 
respiratory and 
cardiovascular comorbid 
conditions 
*Significantly different finding reported in published AMPP study and IBMS data (Bigal et al., 2008; 
Buse et al., 2010; Blumenfeld et al., 2011; Buse et al., 2011 in press)  
**Sources: Natoli et al., 2010; Lipton et al., 2007. 
Table 4. Examples of differences* between chronic migraine and episodic migraine 
3. Defining the burden 
Due to high healthcare costs, manufacturers are under increasing scrutiny by regulators, 
policy-makers, employers and consumers to demonstrate the clinical and economic value 
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of a new drug being brought to market. Given this environment, there is an evolving view 
that the drug approval process is expanding beyond the determination of a drug’s safety 
and efficacy to include data on comparative effectiveness of a new drug to one or more 
available therapies. Comparative effectiveness is defined by the Institution of Medicine as 
“the comparison of effective interventions among patients in typical patient care settings 
with decisions tailored to individual patient needs” (Doyle, 2011; Sox & Greenfield, 2009). 
According to global regulations, demonstrating comparative effectiveness is not required 
for commercial license; however, it is often required for reimbursement by national 
and/or private insurance providers. Specifically, health technology assessments (HTAs) 
are the appraisal process by which public and private payers evaluate economic value 
(Doyle, 2011). In effect, establishing a positive economic value impact has become a 
milestone within the regulatory review and approval of a drug’s lifecycle. By addressing 
research questions highlighted in Table 2, row 3, epidemiologists support industry health 
economists and outcomes researchers in the development of the economic value story by 
providing strategic insight into real-world disease-related burden and resource 
utilization. 
In order to evaluate the real-world value of a drug, many factors and modeling techniques 
that are beyond the scope of epidemiology are employed (Gold et al., 1996; Briggs et al., 
2006). However, epidemiological data and methods can support health economists in 
determining strategy and inputs into economic impact models. A key component when 
assessing the potential value impact of a new drug is to establish the current humanistic, 
societal and economic burden for the disease of interest within the real world. Phase III 
clinical trials are often designed to assess impacts on disease-related burden and economic 
consequences, which include but are not limited to data to evaluate health-related quality of 
life, disability, healthcare encounters and/or workplace impact. However, as burden and 
economic outcomes within a clinical trial setting may not represent outcomes in the real 
world, there is a recognized benefit to supporting the clinical trial data with population-
based assessments that quantify burden and resource utilization (Doyle, 2011; Murray & 
McElwee, 2010; Conway & Clancy, 2010).  
Through leveraging epidemiological data, the humanistic, economic and societal burden 
associated with chronic migraine was established during the development program. 
Specifically, data from the AMPP study, GHC study, and IBMS (Table 3 for study designs) 
was utilized to quantify the burden that frequent migraine attacks pose on patients, their 
families and employers, and healthcare systems.  
In summary, chronic migraine was determined to be a disabling, underdiagnosed and 
costly disorder (Bigal et al., 2008; Blumenfeld et al., 2011; Manack et al., 2011), particularly 
when compared to episodic migraine. Those with chronic migraine often spend at least 
half their days suffering from debilitating pain and associated symptoms of nausea, 
vomiting, photophobia and phonophobia (Bigal et al., 2008; Manack et al., 2011). Data 
support the substantial direct and indirect treatment-associated costs as well as 
significantly increased interference on normal life activities, such as the ability to work or 
perform routine chores and build and maintain functional family, social and community 
relationships, for those with chronic migraine when compared to episodic migraine  
(Table 5). 
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Variable Chronic Migraine Episodic Migraine 
Depression, % meeting 
criteria for clinical depression 
25.2 10 
Headache Impact Test (HIT-
6), % in “severe” category 
72.9 42.3 
Headache-related treatment 
costs, mean US dollars 
$1036 per 3 months $383 per 3 months 
Employment, % on disability 20 (1 in 5) 10 (1 in 10) 
Headache-related Lost 
Productive Time (LPT)* 
50% of sufferers lost more 
than 2 hours per 2 weeks 
16%‡ of sufferers lost more 
than 2 hours per 2 weeks 
LPT associated cost, US 
dollars per week 
 
Women aged 25-64 years: 
$61.51-$118.64 per week 
per person 
Women aged 25-64 years: 
$30.80-$46.49 per week per 
person 
Men aged 25-64 years: 
$62.13-$287.12 per week 
per person 
Men aged 25-64 years: 
$53.15-$86.82 per week per 
person 
*LPT is the sum of self-reported absenteeism and presenteeism during a 2-week period. 
†Significantly different findings were reported in the AMPP study and IBMS (Bigal et al., 2008; Stewart 
et al., 2010; Blumenfeld et al., 2011; Buse et al., 2011 in press; Stokes et al., 2011; Manack et al., 2012; 
Serrano et al., 2011, in progress)  
‡Based on those with fewer than 10 headache days per month. 
Table 5. Examples of burden of chronic migraine compared to episodic migraine† 
4. Post-approval pharmacoepidemiology plan 
The approval to market a drug, device or vaccine depends primarily on the results of the 
clinical trial program which includes investigational trials with a variety of potential 
designs; generally, randomized, double-blind placebo-controlled studies are considered the 
gold standard. However, even these studies are not without limitations, including relatively 
small sample sizes, selective populations, short follow-up, use of intermediate (surrogate) 
endpoints and limited generalizability (Glasser et al., 2007). Furthermore, problems seen 
after product approval has placed demands on manufacturers, regulators and policy makers 
to more effectively monitor and expand the knowledge of safety in the post-authorization 
period. This requires a proactive plan, including an assessment of research gaps and 
appropriate study designs, beginning in the clinical development phase so that strategies 
can be initiated upon drug approval.  
Post-marketing research, or more specifically phase IV studies, can either be 
interventional or non-interventional by design, with epidemiologists typically focusing on 
those that are non-interventional. Again, descriptive or observational designs are used to 
evaluate drug utilization patterns; additionally, with a study design that allows  
for exposure in a broader range of patients, more real-world information about the  
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drug's safety and effectiveness can be captured (Wise, 2011; Glasser et al., 2007). 
Analytical epidemiology or the design, execution and analysis of studies to evaluate 
potential associations between exposure and outcome, has a defined role within 
pharmacovigilance, which deals with the detection, assessment, understanding and 
prevention of adverse effects or other drug-related problems (Wise, 2011; Glasser, et al., 
2007). To this end, post-marketing research has become an integral part of the drug’s 
lifecycle (Wise, 2011; Glasser et al., 2007)  
5. Conclusion 
Epidemiologists provide data, methods and strategic direction to optimize product 
development and commercialization. Key deliverables within the clinical development 
teams include describing and quantifying disease incidence and prevalence, clinical course, 
real-world treatment practices, adverse events rates, patient exposure, and the design, 
analysis and reporting of observational studies. Although an important contribution, data 
from epidemiological studies should not be viewed in isolation, as evaluation of safety and 
efficacy includes data from multiple sources including clinical studies, spontaneous adverse 
event reports and preclinical datasets, and all offer important context. 
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